Home | Publications | Company Information | Top 50 Pharma | AstraZeneca place holder
place holder place holder

AstraZeneca

AstraZeneca Plc

PharmaVitae Profile

Publication Date   July 2008
Publisher   Datamonitor
Product Type   Report
Pages   174
ISBN Number   not applicable
Product Code   DAT1462
Ask a question about this product?

Price £3,010.00

approximately: $4,618 | €3,541

Summary


Introduction

This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark AstraZeneca's performance against key rivals in the ethical pharmaceutical sector
  • Assess the commercial impact of AstraZeneca's recent movement into the biologics market, spearheaded by its acquisition of MedImmune
  • Analyse the exposure of AstraZeneca's blockbuster portfolio to patent expiration and generic competition through to 2013

Content


  • CHAPTER 1 ABOUT THIS PROFILE
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • CHAPTER 2 EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales performance, 2001-13
    • Financial performance, 2001-13
    • AstraZeneca: PharmaVitae forecasts at a glance
    • Strategic insight
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • CHAPTER 3 QUARTERLY NEWS UPDATE
    • Key findings
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • CHAPTER 4 COMPANY STRUCTURE
    • Key findings
    • Company overview
    • Company history
    • M&A history
    • Astra AB and Zeneca Group plc
    • Subsequent M&A activity
    • Abgenix
    • Cambridge Antibody Technology (CAT)
    • KuDOS Pharmaceuticals
    • Arrow Therapeutics
    • MedImmune
    • Albireo
    • M&A strategy
  • CHAPTER 5 COMPANY SALES
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2001-13
    • Product analysis
    • Product analysis, 2001-07
    • Product analysis, 2007-13
    • Therapy area analysis
    • Therapy area analysis, 2001-07
    • Therapy area analysis, 2007-13
    • Therapy area focus, 2001-13
    • Geographic analysis
    • Geographic analysis, 2001-07
    • Geographic analysis, 2007-13
    • Geographic focus, 2001-13
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2007-13
    • Core analysis, 2007-13
    • Expiry analysis, 2007-13
    • Launch/core/expiry configuration, 2007-13
    • Molecule type analysis
    • Molecule type analysis, 2001-07
    • Molecule type analysis, 2007-13
    • Externalization analysis
    • Externalization analysis, 2001-07
    • Externalization analysis, 2007-13
  • CHAPTER 6 COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
    • Financial statements, 2001-07
    • Profit and loss account, 2001-07
    • Balance sheet, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis 2001-07
    • Operating cost ratio and profit margin analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2007-13
    • Operating costs and profit analysis, 2007-13
    • Return on capital employed analysis
    • Capital employed analysis, 2001-07
    • Return on capital employed (RoCE) analysis, 2001-07
    • Market capitalization analysis
    • Market capitalization analysis 2001-07
    • Total shareholder returns (TSR) analysis, 2001-07
  • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
    • Key findings
    • Overview
    • Crestor
    • Crucial differentiation in statin market
    • Potential market share gain via CRP indication
    • Statin market competitor dynamics
    • Positive impact of Zetia/Vytorin setback
    • Combination product with Abbott
    • Betaloc
    • XL formulation finally succumbs to generic competition
    • Nexium
    • PPI franchise lifecycle management
    • PPI market competitor dynamics
    • Generic threat in US market
    • Prilosec/Losec
    • Breakthrough product in GE market
    • Generic competition since 2002
    • Life cycle management
    • Arimidex
    • Following in the footsteps of Tamoxifen
    • ASCO recommendations
    • Aromatase inhibitor market competitor dynamics
    • Recentin
    • What is Recentin?
    • Bullish clinical trial design - taking on Avastin
    • Termination of NSCLC trial
    • Seroquel
    • Robust standing versus rival brands
    • Life cycle management strategy
    • Generic threat in US market
    • Symbicort
    • US market launch
    • Competitor dynamics
    • Lifecycle management strategy & SMART
    • Synagis
    • Monopoly position in RSV market
    • Numax
    • Considerable benefit over Synagis
    • Robust Phase III clinical data
  • CHAPTER 8 APPENDIX
    • R&D pipeline
    • References
    • Abbreviations
  • List of Tables
    • Table 1: AstraZeneca - PharmaVitae forecasts at a glance
    • Table 2: AstraZeneca key product developments, Q1 2008
    • Table 3: AstraZeneca product deals and alliances, Q1 2008
    • Table 4: AstraZeneca technology deals and alliances, Q1 2008
    • Table 5: AstraZeneca M&A activity, 2008
    • Table 6: AstraZeneca company announcements, Q1 2008
    • Table 7: AstraZeneca future product milestones, 2008-10
    • Table 8: AstraZeneca product portfolio overview ($m), 2001-07
    • Table 9: AstraZeneca product portfolio overview ($m), 2007-13
    • Table 10: AstraZeneca therapy portfolio overview ($m), 2001-07
    • Table 11: AstraZeneca therapy portfolio overview ($m), 2007-13
    • Table 12: AstraZeneca portfolio overview by geographic region ($m), 2001-07
    • Table 13: AstraZeneca portfolio overview by geographic region ($m), 2007-13
    • Table 14: AstraZeneca launch portfolio overview ($m), 2007-13
    • Table 15: AstraZeneca core portfolio overview ($m), 2007-13
    • Table 16: AstraZeneca expiry portfolio overview ($m), 2007-13
    • Table 17: AstraZeneca portfolio overview by molecule type ($m), 2001-07
    • Table 18: AstraZeneca product portfolio overview by molecule type ($m), 2007-13
    • Table 19: AstraZeneca product portfolio overview by source ($m), 2001-07
    • Table 20: AstraZeneca product portfolio overview by source ($m), 2007-13
    • Table 21: Total AstraZeneca sales by business unit ($m), 2001-07
    • Table 22: AstraZeneca profit and loss account ($m), 2001-07
    • Table 23: AstraZeneca balance sheet ($m), 2001-07
    • Table 24: AstraZeneca operating revenue/cost analysis ($m), 2001-07
    • Table 25: AstraZeneca operating cost ratio analysis (% of total revenues), 2001-07
    • Table 26: AstraZeneca operating cost ratio analysis (% of total revenues), 2007-13
    • Table 27: AstraZeneca operating revenue/cost analysis ($m), 2007-13
    • Table 28: HPV vaccine royalty payments to AstraZeneca, 2007-13 ($m)
    • Table 29: AstraZeneca capital employed ($m), 2001-07
    • Table 30: AstraZeneca EBIT return on capital employed ($m), 2001-07
    • Table 31: AstraZeneca EBIT pre-tax return/Capital employed driver analysis ($m), 2001-07
    • Table 32: AZN market capitalization ($ billion), 2001-07
    • Table 33: AZN total shareholder returns (annual %), 2001-07
    • Table 34: Key products overview
    • Table 35: Crestor: overview
    • Table 36: Crestor: sales forecast ($m), 2007-13
    • Table 37: Betaloc: overview
    • Table 38: Betaloc: sales forecast ($m), 2007-13
    • Table 39: Nexium: overview
    • Table 40: Nexium: sales forecast ($m), 2007-13
    • Table 41: Prilosec/Losec: overview
    • Table 42: Prilosec/Losec: sales forecast ($m), 2007-13
    • Table 43: Arimidex: overview
    • Table 44: Arimidex: sales forecast ($m), 2007-13
    • Table 45: Recentin: overview
    • Table 46: Recentin: sales forecast ($m), 2007-13
    • Table 47: Seroquel: overview
    • Table 48: Seroquel: sales forecast ($m), 2007-13
    • Table 49: Symbicort: overview
    • Table 50: Symbicort: sales forecast ($m), 2007-13
    • Table 51: Synagis: overview
    • Table 52: Synagis: sales forecast ($m), 2007-13
    • Table 53: Numax: overview
    • Table 54: Numax: sales forecast ($m), 2007-13
    • Table 55: AstraZeneca R&D pipeline (Phase I-Phase III)
  • List of Figures
    • Figure 1: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 2: AstraZeneca financial performance ($m), 2001-13
    • Figure 3: AstraZeneca's blockbuster portfolio sales growth ($m), 2001-13
    • Figure 4: AstraZeneca revenues by molecule type ($m), 2001-13
    • Figure 5: AstraZeneca/MedImmune revenues ($m), 2001-13
    • Figure 6: AstraZeneca SWOT analysis
    • Figure 7: M&A/divestment history AstraZeneca
    • Figure 8: AstraZeneca prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 9: AstraZeneca key sales growth driver & resistors ($m), 2001-07
    • Figure 10: AstraZeneca key sales growth drivers & resistors ($m), 2007-13
    • Figure 11: AstraZeneca prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 12: AstraZeneca prescription pharma sales by therapy area (% of total), 2001-13
    • Figure 13: AstraZeneca prescription pharmaceutical sales by geographic region ($m), 2001-13
    • Figure 14: AstraZeneca drivers and resistors by geographic region ($m), 2001-07
    • Figure 15: AstraZeneca drivers and resistors by geographic region ($m), 2007-13
    • Figure 16: AstraZeneca prescription pharmaceutical sales by geographic region (% of total), 2001-13
    • Figure 17: AstraZeneca launch/core/expiry configuration ($m), 2007-13
    • Figure 18: AstraZeneca prescription pharmaceutical sales by molecule type ($m), 2001-13
    • Figure 19: AstraZeneca growth drivers & resistors by molecule type ($m), 2007-13
    • Figure 20: AstraZeneca prescription pharmaceutical sales by source ($m), 2001-13
    • Figure 21: AstraZeneca growth drivers & resistors by source ($m), 2001-07
    • Figure 22: AstraZeneca growth drivers & resistors by source ($m), 2007-13
    • Figure 23: AstraZeneca operating revenue/cost analysis ($m), 2001-13
    • Figure 24: AstraZeneca operating cost ratio analysis (% of total revenues), 2001-13
    • Figure 25: AstraZeneca return on capital employed, EBIT margin and capital turnover, 2001-07
    • Figure 26: Return on capital employed formula
    • Figure 27: AstraZeneca market capitalization ($m), 2001-07
    • Figure 28: AstraZeneca total shareholder returns ($m), 2001-07